Bausch Health Companies Inc.

NYSE:BHC Stock Report

Market Cap: US$2.8b

Bausch Health Companies Past Earnings Performance

Past criteria checks 0/6

Bausch Health Companies has been growing earnings at an average annual rate of 34.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 1.6% per year.

Key information

34.6%

Earnings growth rate

35.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate1.6%
Return on equityn/a
Net Margin-1.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors

Dec 03

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Oct 10
There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06
Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24
Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Dec 30

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Dec 22

Bausch Health: Things To Consider Before Investing

Dec 11

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Revenue & Expenses Breakdown

How Bausch Health Companies makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:BHC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,474-1783,229605
30 Jun 249,202-4713,090612
31 Mar 248,966-4552,965612
31 Dec 238,757-5922,895604
30 Sep 238,542-9632,789594
30 Jun 238,350-1862,720574
31 Mar 238,150-3572,652545
31 Dec 228,124-2252,531529
30 Sep 228,1272542,514504
30 Jun 228,192432,490492
31 Mar 228,325-4072,504480
31 Dec 218,434-9482,492465
30 Sep 218,451-1,1702,472467
30 Jun 218,478-1,2872,423449
31 Mar 218,042-1,0182,299442
31 Dec 208,027-5602,367452
30 Sep 208,038-1,9232,395447
30 Jun 208,109-2,0432,475467
31 Mar 208,597-1,8882,600476
31 Dec 198,601-1,7882,554471
30 Sep 198,498-6162,512477
30 Jun 198,425-9172,478461
31 Mar 198,401-1,6192,469438
31 Dec 188,380-4,1482,473413
30 Sep 188,422-3,2912,486383
30 Jun 188,505-1,6402,495357
31 Mar 188,610-8052,512357
31 Dec 178,7242,4042,582361
30 Sep 178,9641,3762,609364
30 Jun 179,224-1,1432,645384
31 Mar 179,411-1,4072,657414
31 Dec 169,674-2,4092,782421
30 Sep 1610,024-2,2802,826424
30 Jun 1610,332-1,0132,865424
31 Mar 1610,644-7642,879381
31 Dec 1510,442-2922,700334
30 Sep 159,9065962,481298
30 Jun 159,1758222,288255
31 Mar 158,4841,0012,118241
31 Dec 148,2008812,026246
30 Sep 148,0435021,952246
30 Jun 147,529-7461,804236
31 Mar 146,583-8611,545194
31 Dec 135,766-8661,305157

Quality Earnings: BHC is currently unprofitable.

Growing Profit Margin: BHC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BHC is unprofitable, but has reduced losses over the past 5 years at a rate of 34.6% per year.

Accelerating Growth: Unable to compare BHC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BHC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).

Return on Equity

High ROE: BHC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 21:55
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bausch Health Companies Inc. is covered by 46 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Douglas TsaoBarclays
Ardalan ArfaeiBMO Capital Markets Equity Research